Overview IV Iron-induced Hypophosphatemia After RYGB Status: RECRUITING Trial end date: 2026-06-01 Target enrollment: Participant gender: Summary The primary objective of the study is to compare the incidence of hypophosphatemia in RYGB patients treated with intravenous (IV) single dose of iron isomaltoside (Monofer®) or ferric carboxymaltose (Ferinject®).Phase: PHASE4 Details Lead Sponsor: Lucie FavreTreatments: ferric carboxymaltoseiron isomaltoside 1000